ABOUT US
A comprehensive and integrated solution for the development and the production of your pharmaceutical products
From development of formulations to EU-GMP manufacturing of commercial batches, BePharBel Manufacturing provides a comprehensive and integrated solution for the development and production of your pharmaceutical and para-pharmaceutical products. Our CDMO (Contract Development Manufacturing Organisation) covers all steps of development and production from manufacturing of clinical or commercial batches to analytical services, assistance supply with procurement of raw materials, packaging and serialisation.
Working with BePharBel Manufacturing CDMO means first and foremost a strong commitment on quality thanks to its recently opened European GMP compliant plant, but also and especially thanks to the sound expertise of its teams.
At BePharBel Manufacturing, we produce more than 10 different galenic forms: solid, semi-solid, liquid, non-sterile and sterile (antibiotics, injectables, powder in vials). Driven by the desire to contribute to improving the health of all, BePharBel Manufacturing also boasts an innovative R&D unit which (jointly) develops and files patents for new technologies with the view of making them available to third party partners.
Our strengths are our adaptation capacity and flexibility. Whether for small, medium-sized or large pharmaceutical firms, we provide customised responses to each of our partners.
Since its creation in 2012, on the initiative of a group of experienced and active players in Belgian and international pharmaceutical development, BePharBel Manufacturing has demonstrated dynamism and continually strengthened its position in Belgium and Europe, in particular through the successive takeovers of assets belonging to Propharex (2012), ERFA Pharm (2014), Econophar (2015) and Lagepha (2017).
Today, BePharBel Manufacturing employs almost 80 people, all of whom are chiefly devoted to our production and R&D activities.
Find out more about our CDMO services and our values.
